AvroBio has presented positive updated Phase I/II data of its AVR-RD-04 gene therapy in cystinosis, helping to lift investor sentiment around the company and its lentiviral-based gene therapy platform.
The company’s share price hit rock bottom last year after it abandoned Fabry disease gene therapy candidate AVR-RD-01, but the...